HomeNewsHealthNAFDAC alerts public against use of weight loss pill

NAFDAC alerts public against use of weight loss pill

Date:

Related stories

Obi-Datti presidency, key to national rebirth – LP chieftain

Mr Nwachukwu Nwabueze, a chieftain of the Labour Party...

Buhari celebrates Siene Allwell-Brown at 70

President Muhammadu Buhari says he shares in the joy...

FEC approves N4bn for three projects

The Federal Executive Council (FEC) has approved about N4...

Jigawa govt expresses concern over new Naira notes

The Jigawa government on Wednesday expressed concern over alledged...

NiMet predicts 3-day thick dust haze, sunshine from Thursday

The Nigerian Meteorological Agency (NiMet) has predicted dust haze...

The National Agency for Food and Drugs Administration and Control (NAFDAC) has cautioned Nigerians against the use of the drug  — Weight Rapid Loss Capsule.

The caution is contained in an alert with No. 049/2022, signed by NAFDAC’s Director-General, Prof. Mojisola Adeyeye, issued to the News Agency of Nigeria (NAN) on Sunday in Abuja.

Adeyeye stated that the drug has been found to have potential to cause cancer.

The NAFDAC boss added that result of laboratory analysis showed that the drug, manufactured by Ingi Oman, contain banned substance “phenolphthalein”, which the U.S. Food and Drug Administration recognised as unsafe.

She added that the capsule, being marketed as “the most effective weight loss supplement” and sold through social media platforms like Instagram, also contain microbial growth above permissible limits.

She stated that “phenolphthalein has been found to be toxic to genes, as it can cause damage or mutations in the DNA. Studies have also shown its potential carcinogenic risks.

“NAFDAC implores consumers to stop the purchase and use of the product.

“Members of the public in possession of the product should discontinue use or sale, and submit stock to the nearest NAFDAC office.”

Adeyeye encouraged healthcare professionals and consumers to report any adverse effect experienced with the use of the product to the nearest NAFDAC office.

Consumers are also advised to report adverse effect via p[email protected] or E-reporting platforms available at www.nafdac.gov.ng.

The director-general urged the public to also report any incident concerning the use of the drug via the Med-safety application, which can be downloaded on android and IOS stores.

NAN

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories

LEAVE A REPLY

Please enter your comment!
Please enter your name here